Targeted therapy (overview)

What it is

Targeted therapy uses drugs designed to act on specific molecular changes that drive a tumor — such as a particular mutation or pathway — rather than broadly attacking dividing cells. In gliomas, targeted therapies (such as IDH inhibitors and BRAF/MEK inhibitors) offer precise treatment when actionable molecular changes are identified.

Understanding Targeted therapy (overview)

As the molecular drivers of gliomas have been identified, drugs have been developed to target some of them directly. Targeted therapy aims at a tumor's specific vulnerability — for example, IDH inhibitors target the mutant IDH enzyme in IDH-mutant gliomas, and BRAF/MEK inhibitors target the overactive MAPK pathway in BRAF-altered tumors. When a tumor harbors a change that a targeted drug can act on, this approach can be effective and is often better tolerated than broad chemotherapy. The key requirement is identifying an "actionable" change through molecular testing — which is why comprehensive testing is so valuable, as it can reveal targets and open treatment options (sometimes including clinical trials of newer targeted agents). Not all gliomas have currently actionable targets, and this is an area of active research. Targeted therapy represents the precision-medicine approach to gliomas. Understanding targeted therapy in gliomas clarifies treatment aimed at a tumor's specific molecular changes.

Why it matters

Understanding targeted therapy helps patients and families see the precision-medicine approach — drugs aimed at a tumor's specific molecular changes — and why molecular testing is so valuable for revealing actionable targets and treatment options.